Jessup Wealth Management Inc Invests $6.51 Million in Merck & Co., Inc. $MRK

Jessup Wealth Management Inc purchased a new position in shares of Merck & Co., Inc. (NYSE:MRK) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 61,862 shares of the company’s stock, valued at approximately $6,512,000. Merck & Co., Inc. comprises about 2.2% of Jessup Wealth Management Inc’s portfolio, making the stock its 15th largest position.

Several other institutional investors have also modified their holdings of MRK. Brighton Jones LLC grew its position in shares of Merck & Co., Inc. by 29.5% during the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after acquiring an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in Merck & Co., Inc. by 52.2% in the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after purchasing an additional 3,941 shares during the period. Diversify Advisory Services LLC lifted its holdings in Merck & Co., Inc. by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after purchasing an additional 15,636 shares during the period. Diversify Wealth Management LLC lifted its holdings in Merck & Co., Inc. by 22.2% in the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after purchasing an additional 359,356 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $118.99 on Thursday. Merck & Co., Inc. has a twelve month low of $76.66 and a twelve month high of $125.14. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The company has a market capitalization of $293.89 billion, a price-to-earnings ratio of 33.52, a PEG ratio of 2.69 and a beta of 0.21. The firm has a 50-day moving average of $116.58 and a two-hundred day moving average of $113.02.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The company had revenue of $16.29 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same period in the prior year, the company earned $2.22 EPS. Merck & Co., Inc.’s revenue was up 4.9% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, analysts expect that Merck & Co., Inc. will post 5.17 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 8th. Shareholders of record on Monday, June 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio is presently 95.77%.

Wall Street Analysts Forecast Growth

MRK has been the subject of several research analyst reports. Barclays initiated coverage on shares of Merck & Co., Inc. in a report on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective for the company. Wells Fargo & Company reduced their price objective on shares of Merck & Co., Inc. from $150.00 to $145.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price objective for the company. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Friday, February 13th. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a report on Saturday, June 6th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $128.18.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Wells Fargo reiterated its Buy rating on Merck, adding to the recent analyst support around the stock and reinforcing confidence in the company’s long-term outlook. Wells Fargo Keeps Their Buy Rating on Merck & Company (MRK)
• Positive Sentiment: Merck and Gilead reported positive Phase III HIV data for their once-weekly islatravir/lenacapavir regimen, which could expand Merck’s infectious-disease franchise if regulatory filings proceed as planned. Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
• Positive Sentiment: Merck said it is expanding its EU digital traceability efforts and exploring options to help address the emerging Bundibugyo Ebola outbreak, highlighting new commercial and public-health initiatives. Merck Expands EU Traceability Push And Targets Bundibugyo Ebola Response
• Positive Sentiment: Technical coverage noted that MRK has moved back above its 50-day moving average while staying above its 200-day trendline, with Keytruda growth and pipeline progress supporting the investment case. Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
• Neutral Sentiment: Merck was highlighted in research roundups and conference coverage, but these items were mainly recap-oriented and did not introduce a major new catalyst. Top Research Reports for Merck, Southern Company & Lumentum Merck & Co., Inc. (MRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Merck and Gilead also ended a Phase III non-small-cell lung cancer study after it failed to meet its efficacy bar, which may temper enthusiasm around some of Merck’s oncology pipeline efforts. Will HIV Win and Lung Cancer Loss in Trials Recast Merck’s (MRK) Risk Reward Narrative?

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.